Stemline Therapeutics, Inc.

This study tests two drugs, elacestrant and abemaciclib, in people whose breast cancer has spread to the brain. The goal is to see if the combination can shrink or control brain tumors. About 73 adults with ER-positive, HER2-negative breast cancer will take part. The study is cur…

This study tests a new drug called elacestrant against standard hormone therapy in people with a certain type of early breast cancer that has a high chance of returning. About 4,220 women and men with ER-positive, HER2-negative breast cancer that has spread to lymph nodes will ta…

This early-stage trial tests a new drug called MEN2501 in about 100 adults with ovarian cancer that has stopped responding to platinum-based chemotherapy. The main goals are to find a safe dose and check for side effects. Researchers will also watch for any signs that the drug sh…

This study tests a drug called elacestrant combined with other medicines in people with a common type of advanced breast cancer (ER+/HER2-). The goal is to find safe doses and see if these combinations help stop the cancer from growing. About 435 adults will take part in this ear…

This study tests a new drug combination for adults with a specific type of acute myeloid leukemia (CD123+ AML) who cannot receive standard strong chemotherapy. The treatment adds tagraxofusp to two other drugs (venetoclax and azacitidine) to see if it helps more people achieve co…

This early study tests a new drug called MEN2312 in people with advanced breast cancer that has spread and is not curable. The goal is to find a safe dose and see if it shrinks tumors or slows the cancer. About 240 adults will take the drug alone or with other treatments.